655 related articles for article (PubMed ID: 30478914)
1. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
Pandey K; An HJ; Kim SK; Lee SA; Kim S; Lim SM; Kim GM; Sohn J; Moon YW
Int J Cancer; 2019 Sep; 145(5):1179-1188. PubMed ID: 30478914
[TBL] [Abstract][Full Text] [Related]
2. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
Spring LM; Zangardi ML; Moy B; Bardia A
Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
[TBL] [Abstract][Full Text] [Related]
3. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
Kwapisz D
Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
[TBL] [Abstract][Full Text] [Related]
5. Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies.
Xu XQ; Pan XH; Wang TT; Wang J; Yang B; He QJ; Ding L
Acta Pharmacol Sin; 2021 Feb; 42(2):171-178. PubMed ID: 32504067
[TBL] [Abstract][Full Text] [Related]
6. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
7. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
Piezzo M; Cocco S; Caputo R; Cianniello D; Gioia GD; Lauro VD; Fusco G; Martinelli C; Nuzzo F; Pensabene M; De Laurentiis M
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899866
[TBL] [Abstract][Full Text] [Related]
8. Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer.
Papadimitriou MC; Pazaiti A; Iliakopoulos K; Markouli M; Michalaki V; Papadimitriou CA
Biochim Biophys Acta Mol Cell Res; 2022 Dec; 1869(12):119346. PubMed ID: 36030016
[TBL] [Abstract][Full Text] [Related]
9. The transcriptome of CDK4/6 inhibition.
Knudsen ES; Witkiewicz AK
Aging (Albany NY); 2017 Aug; 9(8):1859-1860. PubMed ID: 28860413
[No Abstract] [Full Text] [Related]
10. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
Scott SC; Lee SS; Abraham J
Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
[TBL] [Abstract][Full Text] [Related]
11. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
Xi J; Ma CX
Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
[TBL] [Abstract][Full Text] [Related]
12. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer.
Scheidemann ER; Shajahan-Haq AN
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830174
[TBL] [Abstract][Full Text] [Related]
13. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
[TBL] [Abstract][Full Text] [Related]
14. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
15. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
17. Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.
O'Brien NA; McDermott MSJ; Conklin D; Luo T; Ayala R; Salgar S; Chau K; DiTomaso E; Babbar N; Su F; Gaither A; Hurvitz SA; Linnartz R; Rose K; Hirawat S; Slamon DJ
Breast Cancer Res; 2020 Aug; 22(1):89. PubMed ID: 32795346
[TBL] [Abstract][Full Text] [Related]
18. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
Laderian B; Fojo T
Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
[TBL] [Abstract][Full Text] [Related]
19. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
Teh JLF; Aplin AE
Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers.
Viswanadhapalli S; Ma S; Sareddy GR; Lee TK; Li M; Gilbreath C; Liu X; Luo Y; Pratap UP; Zhou M; Blatt EB; Kassees K; Arteaga C; Alluri P; Rao M; Weintraub ST; Tekmal RR; Ahn JM; Raj GV; Vadlamudi RK
Breast Cancer Res; 2019 Dec; 21(1):150. PubMed ID: 31878959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]